1Von der Maase H, Sengelov L, Roberts JT, et al. long-term survivalresults of randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in pa- tients with bladder cancer. J Clin Oncol, 2005, 23 (21): 4602-4608. 被引量：1
4Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol, 2002, 14: !8-24. ( PMID11792540 ). 被引量：1
5Rana S, Maples PB, Senzer N, Nemunaitis J. Stathminl: a novel therapeutic target for anticancer activity. Expert Rev Anticancer T- her,2008,8:1461-1470. 被引量：1
6Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/opl 8 as a significant prognostic factor for cervical carcino- ma patients. J Cancer Res Clin Onco1,2009 ,135 :837-846. 被引量：1
7Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer,2009,115:2453-2463. 被引量：1
2Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine mono-therapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000;27:75 -80. 被引量：1
3Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non - small cell lung cancer: a two-stage phase II study. Eur J Cancer, 1997, 33:392 -397. 被引量：1
4Veronesi A, Crivellari D, Magri MD, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer, 1996, 32 : 1809 - 1811. 被引量：1
5The elderly lung cancer vinorelbine Italian study group : effects of vinorelbine on quality of life and survival of elderly patients with ad- vanced non-small-cell lung cancer. J Natl Cancer Inst,1999, 91:66 -72. 被引量：1
6Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study(MILES) phase III randomized rial. J Natl Cancer Inst,2003 ,95 :362 -372. 被引量：1
7Bianco V, Rozzi A, Tonini G, et al. Gemcitabine as single-agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer ( NSCLC ) : a phase II study. Anticancer Res 2002 ; 22 : 3053 - 3056. 被引量：1
8Martoni A,Di Fabio F,Guaraldi M,et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol,2001,24 :614 -617. 被引量：1
9Shepherd F A. Chemotherapy for non-small-cell lung cancer: have we reached a new plateau? Semin Oncol, 1999, 26 ( 1 Suppl4) :3 -11. 被引量：1
10Perez EA,Voge CL,Irwin DH ,et al. Multi-center phase II trial of weekly paclitaxel in women with metastatic breast cancer[J]. J Clin Oncol,2001,19(22) :4216. 被引量：1
